1-2 of 2
Elena Kovalevskaya, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Randomized Comparison of Imatinib 400 Mg Vs. Imatinib + IFN Vs. Imatinib + AraC Vs. Imatinib after IFN Vs. Imatinib 800 Mg: Optimized Treatment and Survival. Designed First Interim Analysis of the German CML Study IV

Ruediger Hehlmann, MD, Susanne Saussele, MD, Michael Lauseker, Ulrike Proetel, MD, Elena Kovalevskaya, MD, Armin Leitner, MD, Claudia Haferlach, MD, Brigitte Schlegelberger, MD, Martin C Müller, MD, Benjamin Hanfstein, MD, Markus Pfirrmann, PhD, Gerhard Ehninger, Thomas Fischer, MD, Joerg Hasford, MD, Andreas Hochhaus, MD, Dieter K. Hossfeld, MD, PhD, Hans- Jochem Kolb, MD, Stefan W Krause, MD, Christoph Nerl, MD, Hans Pralle, MD, Alois Gratwohl, Andreas Tobler, MD, Hermann Heimpel, MD, The German CML Study Group
Journal: Blood
Blood (2008) 112 (11): 184.
https://doi.org/10.1182/blood.V112.11.184.184
Published: 2008
Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Imatinib-Era: High Survival Rate Following Allogeneic HSCT after Imatinib Failure: Results of the German CML Study IV

Susanne Saussele, MD, Michael Lauseker, Alois Gratwohl, MD, Dominik Heim, MD, Dietrich Wilhelm Beelen, MD, Hartmut Döhner, MD, Rainer Schwerdtfeger, MD, Anthony D. Ho, MD, Hans-Jochem Kolb, MD, Markus Pfirrmann, PhD, Martin C. Müller, MD, Armin Leitner, MD, Ulrike Proetel, MD, Elena Kovalevskaya, MD, Claudia Haferlach, MD, Brigitte Schlegelberger, MD, Joerg Hasford, MD, Andreas Hochhaus, MD, Ruediger Hehlmann, MD
Journal: Blood
Blood (2008) 112 (11): 448.
https://doi.org/10.1182/blood.V112.11.448.448
Published: 2008